RTOG News

Minimize
posted on January 03, 2018 11:50
Long-term follow-up results of the NRG Oncology trial NSABP B-31 have shown that the addition of trastuzumab to adjuvant chemotherapy does not negativ...

[Read the rest of this article...]

posted on September 26, 2017 20:00
NRG Oncology trial RTOG 9813 determined that MGMT promoter methylation was an independent predictor of overall survival for patients with anaplastic a...

[Read the rest of this article...]

posted on September 26, 2017 20:00
The utilization of a knowledge-based planning (KBP) model, developed by researchers at the University of Michigan in collaboration with NRG Oncology, ...

[Read the rest of this article...]

posted on September 25, 2017 17:06
 In a new phase III trial report from the National Clinical Trial Network group, NRG Oncology, recurrence-free and overall survival rates for wom...

[Read the rest of this article...]

posted on September 25, 2017 17:05
 NRG Oncology researchers have developed and validated nomograms to predict overall survival (OS), locoregional recurrence (LRR), and distant met...

[Read the rest of this article...]

posted on September 24, 2017 22:50
Long-term follow-up of NRG Oncology trial RTOG 0915 displayed no excess in late-appearing toxicity and similar primary tumor control in both original ...

[Read the rest of this article...]

posted on September 24, 2017 19:00
A recent midpoint follow-up of the NRG Oncology clinical trial RTOG 0526 determined that late treatment-related grade 3, 4, and 5 gastrointestinal (GI...

[Read the rest of this article...]

posted on September 12, 2017 19:35
PHILADELPHIA, PA — NRG Oncology, one of the five funded network groups within the National Cancer Institute (NCI)’s National Clinical Trials Network (...

[Read the rest of this article...]

posted on August 21, 2017 11:41
 PHILADELPHIA, PA —NRG Oncology researchers recently developed and validated a nomogram that can predict 2-year and 5-year overall survival (OS) ...

[Read the rest of this article...]

posted on July 25, 2017 18:09
PHILADELPHIA, PA — NRG-RTOG 0436 has determined that adding an epidermal growth factor receptor (EGFR) inhibitor to a chemo-radiation regimen does not...

[Read the rest of this article...]

Page 1 of 10First   Previous   [1]  2  3  4  5  6  7  8  9  10  Next   Last